A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder
The DOI matches its Crossref record.
Abstract
Objective Two parallel, 8-week double-blind studies compared olanzapine/fluoxetine combination, olanzapine, and fluoxetine in outpatients with treatment-resistant depression (TRD). Method Treatment-resistant depression was defined as a documented history of current-episode antidepressant failure plus a prospective failure on fluoxetine. Following an 8-week fluoxetine lead-in, 605 nonresponders with DSM-IV major depressive disorder were randomly assigned to olanzapine/fluoxetine combination, olanzapine, or fluoxetine. The primary outcome measure was baseline-to-endpoint mean change on the Montgomery-Asberg Depression Rating Scale (MADRS). The study was conducted from April 2002 to May 2005. Results After 8 weeks of double-blind treatment, Study 1 revealed no statistically significant therapy differences in MADRS mean change (olanzapine/fluoxetine combination: -11.0, fluoxetine: -9.4, olanzapine: -10.5). In Study 2, olanzapine/fluoxetine combination demonstrated significantly greater MADRS improvement (-14.5) than fluoxetine (-8.6, p Conclusion Patients with TRD (defined as treatment failure on 2 antidepressants) taking olanzapine/fluoxetine combination demonstrated significantly greater improvement in depressive symptoms than patients taking olanzapine or fluoxetine in 1 of 2 studies and in the pooled analysis. When considered within the context of all available evidence, olanzapine/fluoxetine combination is an efficacious therapy for patients with TRD. Clinical trials registr…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The response and remission rates seen in the antidepressant plus placebo arm were higher than those reported in the Sequenced Treatment Alternatives to Relieve Depression trial for step 3 (response rate, 16.8%; remission rate, 13.7%) and in the olanzapine-fluoxetine study (33)”
Citations
Cites
Still being checked.
Cited by
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Self-citationAnderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Self-citationMcIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Dopamine system dysregulation in major depressive disorders
Belujon, P., & Grace, A. A. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx056 · Cited by 754
“The United States Food and Drug Administration has approved several atypical antipsychotics as supplement to ongoing antidepressant treatment for treatment-resistant patients (Thase et al., 2007; Berman et al., 2009; Kato and Chang, 2013).”
BackgroundBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“…as weight gain and prolactin increase (studies included: Shelton et al. 2001, 2005; Andersen et al. 2005; Corya et al. 2006; Berman et al. 2007; Doree et al. 2007; Mahmoud et al. 2007; McIntyre et al. 2007; Thase et al. 2007; Garakani et al. 2008; Keitner et al. 2009; Nelson and Papakostas 2009).”
BackgroundFedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
Kennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
Self-citationConnolly, K. R., & Thase, M. E. (2011) · Drugs · doi:10.2165/11587620-000000000-00000 · Cited by 462
Self-citationLam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
“There are 4 placebocontrolled RCTs of the olanzapine-fluoxetine combination showing evidence for efficacy in TRD among antidepressant non-responders (e.g., Thase et al., 2007).”
BackgroundTreatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Self-citationSpielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang-Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 234
Citrome, L. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2174 · Cited by 226
Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
Trends in Antipsychotic Drug Use by Very Young, Privately Insured Children
Olfson, M., Crystal, S., Huang, C., & Gerhard, T. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2009.09.003 · Cited by 215
Therapeutic Options for Treatment-Resistant Depression
Shelton, R. C., Osuntokun, O., Heinloth, A. N., & Corya, S. A. (2010) · CNS Drugs · doi:10.2165/11530280-000000000-00000 · Cited by 205
Self-citationZhou, X., Keitner, G. I., Qin, B., Ravindran, A. V., Bauer, M., Del Giovane, C., Zhao, J., Liu, Y., Fang, Y., Zhang, Y., et al. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv060 · Cited by 197
Balu, D. T., Hoshaw, B. A., Malberg, J. E., Rosenzweig-Lipson, S., Schechter, L. E., & Lucki, I. (2008) · Brain Research · doi:10.1016/j.brainres.2008.03.023 · Cited by 194
A longitudinal study of depression and gestational diabetes in pregnancy and the postpartum period
Hinkle, S. N., Buck Louis, G. M., Rawal, S., Zhu, Y., Albert, P. S., & Zhang, C. (2016) · Diabetologia · doi:10.1007/s00125-016-4086-1 · Cited by 185
El-Khalili, N., Joyce, M., Atkinson, S., Buynak, R. J., Datto, C., Lindgren, P., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000015 · Cited by 185
Second-generation antipsychotics for major depressive disorder and dysthymia
Komossa, K., Depping, A. M., Gaudchau, A., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008121.pub2 · Cited by 171
Pharmacological Treatments for Patients with Treatment-Resistant Depression
Ruberto, V. L., Jha, M. K., & Murrough, J. W. (2020) · Pharmaceuticals · doi:10.3390/ph13060116 · Cited by 147
Treatment-Resistant Depression in Primary Care across Canada
Rizvi, S. J., Grima, E., Tan, M., Rotzinger, S., Lin, P., McIntyre, R. S., & Kennedy, S. H. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900702 · Cited by 144
Papakostas, G. I. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8133su1c.03 · Cited by 143
Detke, H. C., DelBello, M. P., Landry, J., & Usher, R. W. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.12.012 · Cited by 135
Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?
Guiard, B. P., & Giovanni, G. D. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00046 · Cited by 131
Waterborne fluoxetine disrupts feeding and energy metabolism in the goldfish Carassius auratus
Mennigen, J. A., Sassine, J. M., Trudeau, V. L., & Moon, T. W. (2010) · Aquatic Toxicology · doi:10.1016/j.aquatox.2010.07.022 · Cited by 152
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Jha, M. K., & Mathew, S. J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230025 · Cited by 114
Shelton, R. C., & Papakostas, G. I. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01130.x · Cited by 112
Keitner, G. I., Garlow, S. J., Ryan, C. E., Ninan, P. T., Solomon, D. A., Nemeroff, C. B., & Keller, M. B. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.003 · Cited by 108
“We do not yet know if difficult-to-treat depression represents a unique subtype (Kupfer and Charney, 2003), or if it is one part of a wide spectrum of depressions that characterize the staging systems (Thase et al., 2007).”
BackgroundResultInfluentialTherapeutic options in treatment-resistant depression
Vieta, E., & Colom, F. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.583675 · Cited by 102
A proposal for an updated neuropsychopharmacological nomenclature
Zohar, J., Nutt, D. J., Kupfer, D. J., Moller, H.-J., Yamawaki, S., Spedding, M., & Stahl, S. M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.08.004 · Cited by 100
Emerging drugs for major depressive disorder
Connolly, K. R., & Thase, M. E. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.660146 · Cited by 96
Self-citationVázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013579 · Cited by 95
Second-generation antipsychotics in the treatment of major depressive disorder: current evidence
Han, C., Wang, S.-M., Kato, M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811901 · Cited by 92
Cusin, C., Iovieno, N., Iosifescu, D. V., Nierenberg, A. A., Fava, M., Rush, A. J., & Perlis, R. H. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08093 · Cited by 93
Papadimitropoulou, K., Vossen, C., Karabis, A., Donatti, C., & Kubitz, N. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1277201 · Cited by 91
Bauer, M., El-Khalili, N., Datto, C. J., Szamosi, J., & Eriksson, H. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.08.032 · Cited by 100
Pharmacologic approaches to treatment resistant depression: Evidences and personal experience
Tundo, A., Filippis, R. D., & Proietti, L. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i3.330 · Cited by 91
Atypical Depression: A Comprehensive Review
Pae, C., Tharwani, H. M., Marks, D. M., Masand, P. S., & Patkar, A. A. (2009) · CNS Drugs · doi:10.2165/11310990-000000000-00000 · Cited by 94
Wright, B. M., Eiland, E. H., & Lorenz, R. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1204 · Cited by 84
Second-generation antipsychotics in major depressive disorder: update and clinical perspective
Chen, J., Gao, K., & Kemp, D. E. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283413505 · Cited by 80
Bortnick, B., El-Khalili, N., Banov, M. D., Adson, D. E., Datto, C. J., Raines, S. R., Earley, W. R., & Eriksson, H. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.031 · Cited by 93
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
Bauer, M., Dell’Osso, L., Kasper, S. F., Pitchot, W., Vansvik, E. D., Köhler, J., Jørgensen, L., & Montgomery, S. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.079 · Cited by 73
Pharmacological interventions for treatment-resistant depression in adults
Davies, P., Ijaz, S., Williams, C. J., Kessler, D., Lewis, G., & Wiles, N. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010557.pub2 · Cited by 73
Edwards, S., Hamilton, V, Nherera, L., & Trevor, N. (2013) · Health Technology Assessment · doi:10.3310/hta17540 · Cited by 71
Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era
Philip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003614781 · Cited by 70
The primacy of mania: A reconsideration of mood disorders
Koukopoulos, A., & Ghaemi, S. N. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.07.006 · Cited by 82
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
Giovanni, G. D., Štrac, D. Š., Solé, M., Unzeta, M., Tipton, K. F., Mück‐Šeler, D., Bolea, I., Corte, L., Perković, M. N., Pivac, N., et al. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00541 · Cited by 84
Antidepressant-like effects of N-acetyl-L-cysteine in rats
Ferreira, F. R., Biojone, C., Joca, S. R. L., & Guimarães, F. S. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283123c98 · Cited by 63
Gao, K., Kemp, D. E., Fein, E., Wang, Z., Fang, Y., Ganocy, S. J., & Calabrese, J. R. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05535gre · Cited by 63
Kato, M., & Chang, C. (2013) · CNS Drugs · doi:10.1007/s40263-012-0029-7 · Cited by 62
Chernoloz, O., Mansari, M. E., & Blier, P. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1611-7 · Cited by 66
Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
Wang, S.-M., Han, C., Lee, S.-J., Jun, T.-Y., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.3.159 · Cited by 56
Brunner, E., Tohen, M., Osuntokun, O., Landry, J., & Thase, M. E. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.101 · Cited by 49
Self-citationBerman, R., Thase, M., Trivedi, M. H., Hazel, Marler, McQuade, Carson, Baker, R. A., & Marcus, R. N. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s18333 · Cited by 54
Self-citationThase, M. E., Trivedi, M. H., Nelson, J. C., Fava, M., Swanink, R., Tran, Q.-V., Pikalov, A., Yang, H., Carlson, B. X., Marcus, R. N., et al. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0603 · Cited by 47
Self-citationUnick, G. J., Snowden, L., & Hastings, J. (2009) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0b013e31819d954f · Cited by 47
Utility of Atypical Antipsychotics in the Treatment of Resistant Unipolar Depression
DeBattista, C., & Hawkins, J. (2009) · CNS Drugs · doi:10.2165/00023210-200923050-00002 · Cited by 50
Korean Medication Algorithm for Depressive Disorders 2017: Third Revision
Seo, J. S., Bahk, W., Wang, H. R., Woo, Y. S., Park, Y. M., Jeong, J., Kim, W. K., Shim, S.-H., Lee, J. G., Jon, D., et al. (2018) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2018.16.1.67 · Cited by 48
Depression, nutritional risk and eating behaviour in older caregivers
Torres, S. J., McCabe, M. P., & Nowson, C. A. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0041-x · Cited by 58
Lazowski, L. K., Townsend, B., Hawken, E. R., Jokic, R., du Toit, R., & Milev, R. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-202 · Cited by 44
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630173522 · Cited by 43
“Two of these studies have shown that OFC was more effective than olanzapine or fluoxetine monotherapy [34, 35] and the other 3 trials did not find significant superiority of OFC for treating TRD [35-37].”
ResultQuesseveur, G., Repérant, C., David, D. J. P., Gardier, A. M., Sánchez, C., & Guiard, B. P. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3434-3 · Cited by 49
The promotion of olanzapine in primary care: An examination of internal industry documents
Spielmans, G. I. (2009) · Social Science & Medicine · doi:10.1016/j.socscimed.2009.05.001 · Cited by 44
Demitrack, M. A., & E.Thase, M. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4312 · Cited by 43
Self-citationWen, X. J., Wang, L. M., Liu, Z. L., Huang, A., Liu, Y. Y., & Hu, J. Y. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20143672 · Cited by 41
Large Intraindividual Variability of Olanzapine Serum Concentrations in Adolescent Patients
Bachmann, C., Haberhausen, M., Heinzel‐Gutenbrunner, M., Remschmidt, H., & Theisen, F. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181633429 · Cited by 45
A review of current evidence for vilazodone in major depressive disorder
Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2013) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2013.794245 · Cited by 37
Sato, H., Ito, C., Hiraoka, K., Tashiro, M., Shibuya, K., Funaki, Y., Yoshikawa, T., Iwata, R., Matsuoka, H., & Yanai, K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4002-2 · Cited by 46
Rogóż, Z. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71515-9 · Cited by 40
Konstantinidis, A., Papageorgiou, K., Grohmann, R., Horvath, A., Engel, R., & Kasper, S. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000745 · Cited by 37
Intranasal esketamine: From origins to future implications in treatment-resistant depression
Sanders, B. J., & Brula, A. Q. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.020 · Cited by 38
Pramipexole for stage 2 treatment-resistant major depression: An open study
Inoue, T., Kitaichi, Y., Masui, T., Nakagawa, S., Boku, S., Tanaka, T., Suzuki, K., Nakato, Y., Usui, R., & Koyama, T. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.035 · Cited by 34
Antipsychotics as antidepressants
Roberts, R. J., Lohano, K., & El‐Mallakh, R. S. (2015) · Asia-Pacific Psychiatry · doi:10.1111/appy.12186 · Cited by 41
Update on Partial Response in Depression
Thase, M. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8133su1c.01 · Cited by 34
Self-citationRecent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders
Jůza, R., Musílek, K., Mezeiová, E., Soukup, O., & Korábečný, J. (2022) · Medicinal Research Reviews · doi:10.1002/med.21923 · Cited by 37
Hassanzadeh, P., & Rahimpour, S. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2120-4 · Cited by 34
Wang, H. R., Woo, Y. S., Ahn, H. S., Ahn, I. M., Kim, H. J., & Bahk, W.-M. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv023 · Cited by 31
The under-recognized role of dopamine in the treatment of major depressive disorder
Montgomery, S. A. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b3cb · Cited by 31
Treatment-Resistant Depression in Poland—Epidemiology and Treatment
Gałecki, P., Samochowiec, J., Mikułowska, M., & Szulc, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030480 · Cited by 38
Olanzapine plus fluoxetine for bipolar disorder: A systematic review and meta-analysis
Silva, M. T., Zimmermann, I. R., Galvão, T. F., & Pereira, M. G. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.11.001 · Cited by 32
Croxtall, J. D., & Scott, L. J. (2010) · CNS Drugs · doi:10.2165/11203830-000000000-00000 · Cited by 30
Antipsychotics as antidepressants: what is the mechanism?
Šagud, M., Mihaljević-Peleš, A., Begić, D., Vuksan‐Ćusa, B., Kramarić, M., Živković, M., & Jakovljević, M. (2011) · PubMed · Cited by 37
Gobbi, G., Ghabrash, M. F., Núñez, N. A., Tabaka, J. M., Sante, J. D., Saint-Laurent, M., Vida, S., Kolivakis, T., Low, N. C. P., Cervantes, P., et al. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000196 · Cited by 31
Quetiapine augmentation in depressed patients with partial response to antidepressants
Olver, J. S., Ignatiadis, S., Maruff, P. T., Burrows, G. D., & Norman, T. R. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.970 · Cited by 31
Pharmacotherapy for Treatment-Resistant Depression
Vas, C., Jain, A., Trivedi, M., Jha, M. K., & Mathew, S. J. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.012 · Cited by 32
Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials
Arbaizar, B., Dierssen‐Sotos, T., Gómez‐Acebo, I., & Llorca, J. (2009) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2009.05.005 · Cited by 28
Nelson, J. C., Thase, M. E., Trivedi, M. H., D, M. F. M., Han, J., Tran, Q.-V., Pikalov, A., Qi, Y., Carlson, B. X., Marcus, R. N., et al. (2009) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.08m00744gre · Cited by 37
Self-citationLuan, S., Wan, H., Wang, S., Li, H., & Zhang, B. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s127453 · Cited by 32
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women
Houston, J., Dharia, S., Bishop, J. R., Ellingrod, V. L., Fijal, B. A., Jacobson, J. G., & Hoffmann, V. P. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.10.020 · Cited by 26
A guide to what works for depression
Jorm, A. F., Allen, N. B., Morgan, A. J., Purcell, R., & Beyondblue (2009) · Swinburne figshare (Swinburne University of Technology) · Cited by 27
Zhang, H., Wang, S., & Quan, Z. (2015) · Molecular Diversity · doi:10.1007/s11030-015-9623-1 · Cited by 26
Bobo, W. V., & Shelton, R. C. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903130609 · Cited by 25
Metadata
- Authors
- Thase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S.
- Affiliations
- University of Pittsburgh (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-02-15
- Volume
- 68
- Issue
- 02
- Pages
- 224-236
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2125094332
- Cited by
- 228
- References
- 0
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 8 · 2023: 7 · 2022: 3 · 2021: 8 · 2020: 3 · 2019: 9 · 2018: 4 · 2017: 8 · 2016: 9 · 2015: 13 · 2014: 15 · 2013: 24 · 2012: 8
- FWCI
- 18.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- treatment-resistant depression, major depressive disorder, olanzapine, fluoxetine, olanzapine-fluoxetine combination, atypical antipsychotics, antidepressant non-response, remission rate, cholesterol, weight gain, hyperglycemia, adverse events, outpatients, Montgomery-Asberg Depression Rating Scale, antidepressant efficacy comparison, antipsychotic augmentation, adjunctive therapy
- MeSH terms
- Olanzapine, Adolescent, Adult, Aged, Benzodiazepines, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Middle Aged, Antipsychotic Agents, Treatment Failure, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.